Joenja® (leniolisib)

About Pharming Group

Pharming Group is a commercial-stage biopharmaceutical company dedicated to serving the unserved rare disease patient. Its strategy is built on a proven operational framework for rare disease drug development, regulatory strategy, and commercialization, currently anchored by its flagship product, Joenja® (leniolisib), for Activated PI3K Delta Syndrome (APDS). The company is executing on a dual-track strategy of maximizing its existing portfolio while advancing a promising pipeline, including a pivotal-stage program in primary mitochondrial diseases, to drive sustainable long-term growth.

About Pharming Group

Pharming Group is a commercial-stage biopharmaceutical company dedicated to serving the unserved rare disease patient. Its strategy is built on a proven operational framework for rare disease drug development, regulatory strategy, and commercialization, currently anchored by its flagship product, Joenja® (leniolisib), for Activated PI3K Delta Syndrome (APDS). The company is executing on a dual-track strategy of maximizing its existing portfolio while advancing a promising pipeline, including a pivotal-stage program in primary mitochondrial diseases, to drive sustainable long-term growth.

Therapeutic Areas